Peroxisome-proliferator-activated receptor 8 agonists

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS FOR DIABETES 183... [Pg.183]

Peroxisome proliferator-activated receptor agonists PPARa agonist Ciglitazone Pioglitazone PPARy agonists WY 14.643... [Pg.391]

Sauerberg, P, Bury, P S., Mogensen, J. R, Deussen, H. J., Pettersson, 1., Fleckner, J., Nehlin, J., Frederiksen, K. S., Albrektsen, T., Din, N., Svensson, L. A., Ynddal, L., Wulff, E. M., Jeppesen, L. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem. 2003, 46, 4883-4894. [Pg.411]

A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. The Journal of Biological Chemistry, 279, 41124-411 30. [Pg.386]

Thiazolidinediones (Gamma-PPAR (peroxisome proliferator-activated receptor) agonists) Pioglitazone, Rosiglitazone... [Pg.469]

Willson, TM and Wahli, W (1997) Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol, 1, 235-241. [Pg.244]

Lin H-R (2012) Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett 22 2954-2958. doi 10.1016/j. bmcl.2012.02.043... [Pg.174]

Thiazolidinediones (PPARy-agonists) Thiazolidine-diones ( pioglitazone, rosiglitazone) lower blood glucose levels in animal models of insulin resistance and also in insulin resistant patients. They are agonists of the peroxisome proliferator-activated receptor y (PPARy). Because they enhance the effect of insulin and reduce serum insulin levels in insulin resistant patients, thiazolidinediones are usually referred to as insulin sensitizers . [Pg.425]

HP-jS-CD were added. All compounds were resolved in 20 min (see Figure 5). The data indicated that the validated method offered equivalent and complementary information, in terms of selectivity, sensitivity, accuracy, linearity, and precision, to that of an established gradient LC method employed for similar purposes. Ragaglitazar is a dual peroxisome proliferator-activated receptor ot and y agonist intended to restore insulin sensitivity and correct diabetic dyslipidemia. A chiral CZE method combining two CDs, sulfobutylether-jS-CD and dimethyl-/i-CD, lent itself to the analysis of ragaglitazar, its distomer (the (+)... [Pg.276]

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2... [Pg.117]

Netoglitazone is an insulin sensitizer currently in Phase II clinical trials. It is able to modulate both PPAR-a and PPAR-y subtypes of peroxisome proliferator-activated receptor (Phase ll). Metaglidasen (MBX-102) is the (—)-enantiomer of the NSAID halofenate. This selective PPAR-y nuclear receptor agonist is being evaluated (Phase II) as an insulin sensitizer. It is structurally different from the currently marketed glitazones (Figure 8.84). ... [Pg.332]

Mechanism of Action Potent and highly selective agonist for peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) which decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. [Pg.105]

Philips J-C, Petite C, Willi J-P, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor 8 agonist rosiglitazone on dedifferentiated thyroid cancers. Nucl Med Comm 2004 25 1183-6. [Pg.471]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...